Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC · Real-Time Price · USD
2.640
+0.140 (5.60%)
At close: Apr 2, 2025, 4:00 PM
2.400
-0.240 (-9.09%)
After-hours: Apr 2, 2025, 7:56 PM EDT
Ensysce Biosciences Revenue
In the year 2024, Ensysce Biosciences had annual revenue of $5.21M with 133.58% growth. Ensysce Biosciences had revenue of $1.30M in the quarter ending December 31, 2024, with 153.12% growth.
Revenue (ttm)
$5.21M
Revenue Growth
+133.58%
P/S Ratio
0.33
Revenue / Employee
$651,254
Employees
8
Market Cap
3.71M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ENSC News
- 2 days ago - Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Accesswire
- 15 days ago - Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain - Accesswire
- 23 days ago - Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results - Accesswire
- 4 weeks ago - Ensysce Biosciences to Participate in the 37th Annual ROTH Conference - Accesswire
- 4 weeks ago - Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids - PRNewsWire
- 2 months ago - Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment - Accesswire
- 2 months ago - Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR - Accesswire
- 3 months ago - Ensysce Biosciences Issues Annual Shareholder Letter - Accesswire